Alkem Laboratories Ltd Hits Intraday Low Amid Price Pressure on 13 Feb 2026

Intraday Performance and Price Movement

On 13 Feb 2026, Alkem Laboratories Ltd’s share price fell sharply, registering a day change of -5.09%. The stock reached an intraday low of Rs 5,596.1, marking a 4.48% drop from its previous close. This decline was more pronounced than the Pharmaceuticals & Biotechnology sector’s average, with Alkem underperforming the sector by 3.52% on the day. The stock’s performance also lagged behind the Sensex, which declined by 1.04% during the same period.

The stock has now recorded losses for two consecutive sessions, with a cumulative return decline of -4.69% over this period. This downward momentum reflects immediate selling pressure and a cautious market stance towards the stock in the short term.

Technical Indicators and Moving Averages

From a technical perspective, Alkem Laboratories Ltd’s current price remains above its 200-day moving average, indicating a longer-term support level. However, the stock is trading below its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term weakness. This positioning suggests that recent price action has been subdued relative to its recent trading range, contributing to the intraday lows observed.

Market Context and Broader Index Movements

The broader market environment also exerted pressure on Alkem Laboratories Ltd’s shares. The Sensex opened sharply lower by 772.19 points and was trading at 82,800.86 at the time of reporting, down 1.04%. Despite this decline, the Sensex remains relatively close to its 52-week high of 86,159.02, being just 4.06% below that peak. The index is trading below its 50-day moving average, although the 50-day average itself is positioned above the 200-day moving average, indicating mixed signals for market momentum.

Comparative Performance Analysis

Examining Alkem Laboratories Ltd’s performance over various time frames reveals a pattern of underperformance relative to the Sensex. The stock’s one-day return of -5.44% contrasts with the Sensex’s -1.05%. Over the past week, Alkem declined by 2.56%, while the Sensex fell by 0.94%. The one-month performance shows a similar trend, with Alkem down 5.47% compared to the Sensex’s 0.99% decline. Over three months, the stock’s return was -3.20%, lagging behind the Sensex’s -1.99%.

Despite these recent setbacks, Alkem Laboratories Ltd has outperformed the Sensex over longer horizons. Its one-year return stands at 17.24%, nearly double the Sensex’s 8.74%. Year-to-date, the stock has marginally gained 0.62%, while the Sensex has declined by 2.84%. Over three, five, and ten years, Alkem’s returns of 69.59%, 93.10%, and 319.97% respectively, have significantly surpassed the Sensex’s corresponding returns of 37.01%, 60.63%, and 260.20%. This long-term outperformance highlights the stock’s historical resilience despite short-term volatility.

Mojo Score and Rating Update

Alkem Laboratories Ltd currently holds a Mojo Score of 62.0, categorised as a Hold. This represents a downgrade from its previous Buy rating, which was changed on 1 Dec 2025. The company’s Market Cap Grade is 2, reflecting its mid-tier market capitalisation status within the Pharmaceuticals & Biotechnology sector. The rating adjustment and score reflect a more cautious stance based on recent price action and market conditions.

Sector and Industry Considerations

Operating within the Pharmaceuticals & Biotechnology sector, Alkem Laboratories Ltd’s recent price pressure is notable given the sector’s overall performance. The sector itself has experienced volatility, influenced by broader market trends and sector-specific factors. Alkem’s underperformance relative to its sector peers on the day indicates specific pressures impacting the stock beyond general market movements.

Summary of Immediate Pressures and Market Sentiment

The sharp intraday decline in Alkem Laboratories Ltd’s share price reflects immediate selling pressure amid a broader market downturn. The stock’s fall below multiple short- and medium-term moving averages signals a cautious sentiment among market participants. While the Sensex and sector indices have also declined, Alkem’s steeper drop indicates specific factors influencing its price action today.

Despite the current weakness, the stock’s position above the 200-day moving average suggests some underlying long-term support. However, the recent downgrade in its Mojo Grade from Buy to Hold and the negative short-term technical indicators highlight a period of consolidation or correction. Market participants appear to be reassessing the stock’s near-term prospects in light of prevailing market conditions and sector dynamics.

Overall, the day’s trading session for Alkem Laboratories Ltd was characterised by notable price pressure, with the stock touching its intraday low amid broader market weakness and sector underperformance. The immediate outlook remains cautious as the stock navigates these pressures.

Unlock special upgrade rates for a limited period. Start Saving Now →